clinical trial · NCT05682560
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
StemCyte, Inc.·phase2·completed·n = 30
Long COVIDPost-COVID SyndromePost COVID-19 ConditionREGENECYTEPlacebo
brief summary
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
started
May 4, 2023
primary completion
Jul 26, 2024
completion
Feb 27, 2025
last updated
Mar 24, 2025
detailed description
This is a two-arm, single-center, single-blind, randomized, placebo-controlled phase IIa study. A total of 30 subjects with post-COVID will be enrolled.
official title
A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol